Pair page
Cagrilintide with Eloralintide
Mechanism-tag overlap and published literature for Cagrilintide and Eloralintide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
long-acting-amylin-analog
selective-amylin-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cagrilintide and Eloralintide have published these mechanism-level observations. Not a co-administration recommendation.
Novo Nordisk's long-acting amylin analog. Same drug class, broader receptor activity (non-selective). Cagrilintide is the established amylin comparator; eloralintide's preclinical taste-avoidance and Phase 2 tolerability data position it as the selective-receptor challenger in this class.
Quick facts
Cagrilintide
Eloralintide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| — | Cagrilintide | ClinicalTrials.gov. REDEFINE 1 (NCT05567796) and REDEFINE 2 (NCT05394519). Novo Nordisk CagriSema Phase 3 program. | human trial, Phase 3 |
| 2023 | Cagrilintide | Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. | human trial, Phase 2 |
| 2023 | Cagrilintide | Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. (Comparator.) PMID 37366315 | human trial, Phase 2 |
| 2021 | Cagrilintide | Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. | human trial, Phase 2 |
| 2025 | Cagrilintide | Garvey WT, Frias JP, Jastreboff AM, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. DOI: 10.1056/NEJMoa2502081. | human trial |
| 2025 | Cagrilintide | Davies MJ, Frias JP, Jastreboff AM, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. PMID: 40544432. DOI: 10.1056/NEJMoa2502082. PMID 40544432 | human trial |
| 2022 | Cagrilintide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator.) PMID 35658024 | human trial |
| 2021 | Cagrilintide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator.) PMID 33567185 | human trial |
| 2025 | Cagrilintide | Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. (Novo Nordisk next-generation successor to CagriSema.) | human trial, Phase 1 |
| 2021 | Cagrilintide | Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286)… PMID 33894838 | human trial, Phase 1 |
| 2018 | Cagrilintide | Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175(1):3-17. PMID: 29059473. PMID 29059473 | review |
| 2021 | Cagrilintide | Kruse T, Dahl K, Frigeri P, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Endocrinology. 2021;162(6):bqab057. PMID: 33727283. PMID 33727283 | research article |
| 2025 | Eloralintide | Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Press release, November 6, 2025. (Phase 2 topline announcement; Phase 3 enrollment initi… | human trial, Phase 3 |
| 2025 | Eloralintide | Billings LK, Hansen HH, Dam-Larsen S, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID: 41207310. (NCT06230523 — pivotal Phase 2; up to 20… PMID 41207310 | human trial, Phase 2 |
| 2023 | Eloralintide | Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730.… PMID 37515693 | human trial, Phase 2 |
| 2021 | Eloralintide | Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID:… PMID 34798049 | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06230523 — A Study of LY3841136 in Adult Participants With Obesity or Overweight. (Pivotal Phase 2.) | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06603571 — A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. (Combination Phase 2.) | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06297616, NCT06916091 — Additional Phase 2 eloralintide monotherapy programs. | human trial, Phase 2 |
| 2025 | Eloralintide | Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2025. PMID: 41559929. (Phase 1 multiple-ascending-dose results; 100 participants, up to ~11% weight loss at 12 weeks.) PMID 41559929 | human trial, Phase 1 |
| — | Eloralintide | ClinicalTrials.gov NCT05295940 — A Study of LY3841136 in Healthy Participants. (Phase 1 SAD/MAD.) | human trial, Phase 1 |
| 2025 | Eloralintide | Briere DA, Bueno AB, Gimeno RE, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. PMID: 41109426. (Full translational characterization; AMY1R selectivity, preclinical weigh… PMID 41109426 | preclinical, in vivo |
| 2025 | Eloralintide | Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes 2025;74(Suppl 1):849-P. (ADA 2025 scientific sessions prec… | preclinical, in vivo |
| 2025 | Eloralintide | Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat Rev Endocrinol. 2025;21:482-494. (Modern review of the amylin drug class including eloralintide context.) | review |
Related pair pages
More research context
Frequently asked
Have Cagrilintide and Eloralintide been studied together?
Researchers have published mechanistic-level co-administration discussion of Cagrilintide and Eloralintide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cagrilintide and Eloralintide share?
Cagrilintide and Eloralintide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cagrilintide and Eloralintide?
Cagrilintide: Investigational; CagriSema under review. Eloralintide: Investigational — Phase 3 enrollment initiated late 2025. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cagrilintide and Eloralintide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cagrilintide profile and the Eloralintide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026